X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cabozantinib (452) 452
index medicus (263) 263
oncology (235) 235
humans (207) 207
cancer (122) 122
metastasis (110) 110
male (89) 89
sorafenib (82) 82
everolimus (79) 79
sunitinib (75) 75
female (72) 72
antineoplastic agents - therapeutic use (71) 71
vandetanib (69) 69
c-met (67) 67
pharmacology & pharmacy (67) 67
open-label (66) 66
met (65) 65
middle aged (63) 63
targeted therapy (63) 63
renal cell carcinoma (61) 61
angiogenesis (55) 55
animals (55) 55
care and treatment (54) 54
double-blind (54) 54
thyroid cancer (54) 54
carcinoma (52) 52
protein kinase inhibitors - therapeutic use (51) 51
nivolumab (50) 50
pyridines - therapeutic use (49) 49
tyrosine kinase inhibitor (49) 49
anilides - therapeutic use (48) 48
tyrosine (48) 48
vascular endothelial growth factor (48) 48
analysis (47) 47
survival (47) 47
aged (46) 46
chemotherapy (46) 46
treatment outcome (46) 46
endothelial growth-factor (44) 44
inhibitor (43) 43
prostate cancer (43) 43
tumors (43) 43
adult (40) 40
expression (40) 40
carcinoma, renal cell - drug therapy (39) 39
patients (39) 39
research (39) 39
therapy (39) 39
axitinib (37) 37
clinical trials (37) 37
drug therapy (37) 37
medicine & public health (37) 37
renal-cell carcinoma (37) 37
tyrosine kinase inhibitors (37) 37
carcinoma, renal cell (36) 36
immunotherapy (36) 36
kinases (36) 36
cancer therapies (35) 35
kidney neoplasms - drug therapy (35) 35
medullary-thyroid cancer (35) 35
metastases (35) 35
kidney cancer (34) 34
trial (34) 34
antineoplastic agents - pharmacology (33) 33
review (33) 33
xl184 (33) 33
article (32) 32
lenvatinib (32) 32
mutation (32) 32
urology & nephrology (32) 32
medical prognosis (31) 31
pazopanib (31) 31
phase-ii (31) 31
pyridines - pharmacology (31) 31
ret (31) 31
disease-free survival (30) 30
interferon-alpha (30) 30
thyroid neoplasms - drug therapy (30) 30
mutations (29) 29
anilides - pharmacology (28) 28
cell lung-cancer (28) 28
health aspects (28) 28
phase-ii trial (28) 28
pyridines - administration & dosage (28) 28
anilides - administration & dosage (27) 27
protein kinase inhibitors - pharmacology (27) 27
cell line, tumor (26) 26
growth (26) 26
medullary thyroid cancer (26) 26
molecular targeted therapy (26) 26
resistance (26) 26
pharmacokinetics (25) 25
antineoplastic agents - adverse effects (24) 24
hepatocellular carcinoma (24) 24
neoplasm metastasis (24) 24
proto-oncogene proteins c-ret - genetics (24) 24
anilides - adverse effects (23) 23
mice (23) 23
prognosis (23) 23
pyridines - adverse effects (23) 23
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 03/2016, Volume 374, Issue 9, pp. 889 - 890
Journal Article
Cancer Discovery, ISSN 2159-8274, 12/2018, Volume 8, Issue 12, pp. 1529 - 1539
We present a cohort of 41 patients with osimertinib resistance biopsies, including 2 with an acquired CCDC6-RET fusion. Although RET fusions have been... 
LUNG-CANCER | CABOZANTINIB | TKI | ONCOLOGY | MUTATION | ERLOTINIB | AZD9291
Journal Article
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, ISSN 0027-8874, 06/2019, Volume 111, Issue 6, pp. 575 - 583
Background Liquid biopsy for plasma circulating tumor DNA (ctDNA) next-generation sequencing (NGS) is commercially available and increasingly adopted in... 
CABOZANTINIB | OPEN-LABEL | PHASE-2 | ONCOLOGY | ADENOCARCINOMAS | CELL-FREE DNA
Journal Article
Oncogene, ISSN 0950-9232, 05/2016, Volume 35, Issue 21, pp. 2687 - 2697
Antiangiogenic therapy resistance occurs frequently in patients with metastatic renal cell carcinoma (RCC). The purpose of this study was to understand the... 
ACTIVATION | METASTASIS | ANGIOGENESIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | CANCER | CELL BIOLOGY | RECEPTOR TYROSINE KINASES | CABOZANTINIB XL184 | ONCOLOGY | C-MET | GROWTH | GENETICS & HEREDITY | EXPRESSION | PROGRESSION | Proto-Oncogene Proteins c-met - metabolism | Humans | Drug Resistance, Neoplasm | Molecular Targeted Therapy | Sunitinib | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Carcinoma, Renal Cell - enzymology | Indoles - pharmacology | Carcinoma, Renal Cell - drug therapy | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Signal Transduction | Carcinoma, Renal Cell - pathology | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Angiogenesis Inhibitors - pharmacology | Proto-Oncogene Proteins - genetics | Receptor Protein-Tyrosine Kinases - metabolism | Proto-Oncogene Proteins c-met - genetics | Xenograft Model Antitumor Assays | Pyrroles - pharmacology | Animals | Receptor Protein-Tyrosine Kinases - genetics | Mice, Nude | Kidney Neoplasms - enzymology | Kidney Neoplasms - pathology | Cell Proliferation - drug effects | Mice | Kidney Neoplasms - drug therapy | Molecular targeted therapy | Genetic aspects | Carcinoma, Renal cell | Drug therapy | Drug resistance | Properties | Phosphotransferases | Methods | Cancer therapies | Kidney cancer | Metastasis | Index Medicus | Cabozantinib | Renal Cell Carcinoma | AXL | MET
Journal Article
ONKOLOGE, ISSN 0947-8965, 03/2017, Volume 23, Issue 3, pp. 232 - 233
Journal Article
Cancer Discovery, ISSN 2159-8274, 03/2019, Volume 9, Issue 3, pp. 384 - 395
RET fusions are oncogenic drivers of various tumors, including non-small cell lung cancers (NSCLC). The safety and antitumor activity of the multikinase RET... 
CELL LUNG-CANCER | CABOZANTINIB | ONCOLOGY | REARRANGEMENTS | Index Medicus
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 01/2018, Volume 24, Issue 1, pp. 204 - 213
Purpose: Efforts to discover drugs that overcome resistance to targeted therapies in patients with rare oncogenic alterations, such as NTRK1 and ROS1... 
CABOZANTINIB | ONCOGENE | ONCOLOGY | CRIZOTINIB RESISTANCE | INHIBITOR | PROTEINS | CHEMOTHERAPY
Journal Article
Thyroid, ISSN 1050-7256, 06/2019, Volume 29, Issue 6, pp. 83 - 844
Background: Medullary thyroid carcinoma (MTC) presents a disproportionate number of thyroid cancer deaths due to limited treatment options beyond surgery.... 
Thyroid Cancer and Nodules | microRNAs | tyrosine kinase inhibitors | tumor suppressors | cabozantinib resistance | targeted intravenous delivery | nanocells | MIGRATION | CABOZANTINIB | PROLIFERATION | TARGETING SNAI1 | CELL LUNG-CANCER | INVASION | GASTRIC-CANCER | PATHWAY | ENDOCRINOLOGY & METABOLISM | TUMOR-SUPPRESSOR | NODAL METASTASIS
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 06/2015, Volume 102, Issue 6, pp. 501 - 508
Therapeutic arsenal in prostate cancer widens for several years. New hormonal therapies such as acetate abiraterone or enzalutamide were the first molecules to... 
Cabozantinib | Abiraterone | MOSCATO | Enzalutamide | CRPC
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 01/2017, Volume 23, Issue 1, pp. 204 - 213
Purpose: Efforts to discover drugs that overcome resistance to targeted therapies in patients with rare oncogenic alterations, such as NTRK1 and ROS1... 
CABOZANTINIB | ONCOGENE | ONCOLOGY | CRIZOTINIB RESISTANCE | INHIBITOR | REARRANGEMENTS | PROTEINS | ROS1 | CHEMOTHERAPY
Journal Article
BLOOD, ISSN 0006-4971, 07/2019, Volume 134, Issue 1, pp. 30 - 43
The era of targeted therapies has seen significant improvements in depth of response, progression-free survival, and overall survival for patients with... 
MULTIPLE-MYELOMA | TYROSINE KINASE AXL | CABOZANTINIB | TECHNOLOGIES | INHIBITION | GENE | BONE METASTASIS | PROLIFERATION | HEMATOLOGY | EXPRESSION | SOFTWARE
Journal Article
Cancer Discovery, ISSN 2159-8274, 07/2018, Volume 8, Issue 7, pp. 836 - 849
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non-small cell lung cancer... 
CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | CABOZANTINIB | ONCOLOGY | ADENOCARCINOMA | CRIZOTINIB | RESISTANCE | OPEN-LABEL | FUSIONS | CHEMOTHERAPY | CHRONIC MYELOID-LEUKEMIA
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 08/2019, Volume 25, Issue 16, pp. 4924 - 4932
Purpose: Aberrant activation of MET (hepatocyte growth factor receptor) signaling is implicated in the tumorigenesis of human cancers. This phase I study... 
TRIAL | CABOZANTINIB | AMPLIFICATION | ONCOLOGY | GROWTH | CRIZOTINIB | RESISTANCE | SUNITINIB | VOLITINIB | RENAL-CELL CARCINOMA | DISCOVERY | Index Medicus
Journal Article
American Journal of Surgical Pathology, ISSN 0147-5185, 08/2018, Volume 42, Issue 8, pp. 1121 - 1126
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2018, Volume 36, Issue 36, pp. 3529 - 3532
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2019, Volume 30, Issue 1, pp. 6 - 8
Journal Article
Cancer discovery, ISSN 2159-8274, 7/2017, Volume 7, Issue 7, pp. 750 - 765
Several kinase inhibitors that target aberrant signaling pathways in tumor cells have been deployed in cancer therapy. However, their impact on the tumor... 
prostate cancer | kinase inhibitors | innate immunity | neutrophils | cabozantinib
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.